Lilly’s weight-loss pill shows better blood sugar control in late-stage trials
Eli Lilly‘s experimental weight-loss pill showed superior blood sugar control in diabetic patients across two late-stage trials, the company said on Wednesday, as it seeks to widen its lead in the rapidly growing market for GLP-1 drugs. The oral drug, orforglipron, is designed to mimic the appetite-suppressing GLP-1 hormone targeted by the company’s blockbuster injection…